Pawsible Ventures' First Cohort Maps the Pet-Health Infrastructure Bet

Pawsible Ventures, a pet-health venture fund and studio backed by publicly-traded Victory Square Technologies (CSE: VST), unveiled its inaugural cohort on April 23: eight companies selected from several hundred global applicants. The list itself is the story. Rather than scattered bets across consumer products and retail, the cohort clusters tightly around a single thesis: the infrastructure underneath veterinary clinics, pet-care facilities, and pet-owner diagnostics is underbuilt, and whoever fills it captures rent on the entire $300B category.

What Happened

Pawsible Ventures launched in October 2025 as a $10M Fund I and venture studio, positioning itself as both a check-writer and a hands-on builder for early-stage pet-health companies. The April 23 announcement formalizes the first cohort: eight companies selected from several hundred applicants, organized explicitly around what Pawsible calls "the infrastructure layer."

The cohort:

Lab4Paws — Preclinical veterinary CRO and biobank, supplying cells, media, assays, and reagents for animal-health pharma and biotech R&D.

VetHubRx — Electronic prescribing platform for veterinary clinics, replacing fax-based workflows. Growing through word-of-mouth, per the release.

NerveX (NxVET) — A bioelectronic device (NxSCOPE) that attaches to a standard stethoscope to capture voice and vitals, integrating with AI scribe platforms. The release notes "thousands of records generated across hundreds of clinics."

Charlie Pet Health — Preventative health platform combining biomarker testing, longitudinal tracking, and AI, with diagnostic and radiology partnerships already in place.

Rooted Owl — Science-backed pet supplements with national retail distribution (Chewy, Amazon, Petco, Tomlinson's) through wholesalers Zeigler's and Nelson Wholesale. Carries the NASC Quality Seal.

Tato — AI-native operating system for pet-care businesses, combining a 24/7 AI receptionist with a CRM for memberships and payments. Serves 65,000+ pet parents and processes roughly $780K in annualized GMV through the platform.

Vetr Health — Membership-based mobile veterinary primary care, with its own software platform for mobile vets. Accepted into Google's AI Accelerator.

PupPilot — AI front-office platform for veterinary clinics, with over 130 PIMS integrations and the ability to read patient medical records for context-aware responses.

Pawsible co-founder Alex Chieng framed the selection in structural terms, saying every company in the cohort is "solving something the industry has ignored for too long." Shafin Diamond Tejani, CEO of parent Victory Square Technologies, called pet health "a $300B+ market hiding in plain sight."

Applications for Cohort 2 open later in 2026.

Why It Matters

On its own, a cohort announcement is the lightest form of venture news. No disclosed check sizes per company, no valuations, no commercial commitments. But the composition of this cohort is informative in several ways operators should track.

1. The AI clustering is not subtle. Four of the eight companies are explicitly AI-native: NxVET's integration with AI scribes, Tato's AI receptionist, PupPilot's front-office automation, and Charlie's AI-enabled health tracking. The NxVET hardware-as-substrate-for-AI play and Charlie's biomarker + longitudinal tracking approach suggest Pawsible is betting that the AI layer enters pet health through clinics and mobile-vet workflows first, not through consumer apps. That is a meaningfully different thesis from the Mars Petcare Companion Fund, which has historically been more category-agnostic and consumer-adjacent.

2. Several cohort companies already have revenue. Tato discloses roughly $780K in annualized GMV across paying customers in dog bars, daycare, and grooming. Rooted Owl sits on shelves at Chewy, Amazon, Petco, and Tomlinson's. NxVET has generated "thousands of records" from "hundreds of clinics." This is not a seed-stage research portfolio. Several of these companies are at the traction stage where the next 12 to 24 months should surface either Series A rounds or strategic partnerships.

3. The vet-practice layer is the most concentrated bet. Five of the eight companies sell directly into veterinary clinics or corporate vet networks (Lab4Paws, VetHubRx, NxVET, PupPilot, Vetr Health). Charlie Pet Health has vet and radiology partnerships. Only Rooted Owl and Tato primarily sell outside the clinic. For corporate vet operators such as Mars Veterinary Health, NVA, Heartland Veterinary Partners, Thrive Pet Healthcare, and PetVet Care Centers, the cohort is effectively a scouting list of software, diagnostic, and device vendors to evaluate or partner with.

4. Pawsible's own financing profile is the least-discussed constraint. A $10M Fund I is modest relative to the $300B market framing and to peer accelerators.

Per Pawsible's launch disclosures, the fund plans to deploy into up to 20 companies over three years, which paces out to roughly $500K per company on average before follow-on — appropriate for pre-seed incubation but well short of what it takes to lead a Series A.

For context, Mars Petcare and Digitalis Ventures' Companion Fund II is a $300M vehicle — 30x Pawsible's Fund I — and already holds positions in Smalls, MySimplePetLab, and Scratch, among others.

Pawsible's structural question for 2026 is whether the thematic concentration on infrastructure gives it enough scout equity to graduate to a larger Fund II before the traction-stage companies in this cohort (Tato, NxVET, Charlie) need institutional Series A checks it can't write.

5. The timing alongside other category signals is not coincidence. In the same week as this announcement, Mars's Waltham Petcare Science Institute published the first AI-supported canine periodontal disease risk-assessment model (April 23), and Kennel Connection surfaced its exclusive clinical-grade PCR partnership with Petwealth (April 22). Three separate actors, an incumbent (Mars), a software platform (Kennel Connection), and an early-stage venture studio (Pawsible), converged on the same structural thesis within 48 hours: the preventive-care and infrastructure layer of pet health is being re-platformed.

What to Watch

Follow-on rounds from cohort companies. The clearest signal of Pawsible's picking discipline will be where Tato, NxVET, and Charlie Pet Health raise next, including check size, lead investor, and whether any incumbents (Zoetis, IDEXX, Mars, Covetrus) participate. A strategic on any of these cap tables within 12 months would materially elevate Pawsible's status as a scout.

Cohort 2 composition. Does Pawsible continue the vet-practice concentration, or broaden into diagnostics, therapeutics, or consumer? A consistent infrastructure thesis across two cohorts is itself a signal.

A drift toward consumer products would suggest Cohort 1's clustering was opportunistic rather than strategic.

Victory Square Technologies' disclosures. As a public parent, VST's financial filings will reveal how much capital is actually committed to Pawsible beyond the announced $10M Fund I, how aggressively follow-on capital is reserved, and whether any outside LPs sit alongside the VST balance sheet.

Watch VST's next quarterly update.

Partnership or exit signals within the cohort. The highest-leverage read on Pawsible's value-add will come from the first strategic partnership or commercial deal one of its cohort companies lands. Watch especially for Tato (category-adjacent to Gingr, PetDesk, Time to Pet, and Kennel Connection, and therefore a natural acquisition target for any of them) and PupPilot (competes with Shepherd, VetBadger, and Covetrus Pulse on the clinic-front-office side, where consolidation is already underway).

Source: Pawsible Ventures press release via PR Newswire